<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04603586</url>
  </required_header>
  <id_info>
    <org_study_id>Changhai Hospit</org_study_id>
    <nct_id>NCT04603586</nct_id>
  </id_info>
  <brief_title>Stereotactic Radiotherapy in Locally Advanced Pancreatic Cancer With Different Biological Effective Doses</brief_title>
  <official_title>A Prospective Phase Ⅱ Clinical Study of Stereotactic Radiotherapy Combined With Chemotherapy With Different Biological Effective Doses (60-70gy vs. &gt;70Gy) in Locally Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the safety and efficacy of SBRT in LAPC with different&#xD;
      biological effective dose (BED) (60-70Gy Vs.&gt;70Gy ) , to identify a dose range that could&#xD;
      achieve better survival benefit and minimize the toxicity of radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 20, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year Disease Progression-Free-Survival (DPFS)</measure>
    <time_frame>1-year</time_frame>
    <description>Disease Progression-Free-Survival (DPFS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Probability of gastrointestinal (GI) Toxicity</measure>
    <time_frame>1-year</time_frame>
    <description>gastrointestinal (GI) toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year Local Control Rate</measure>
    <time_frame>1-year</time_frame>
    <description>Local Control Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1-year</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Treatment</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SBRT with BED 60-70Gy combined with Gemcitabine + albumin-bound paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SBRT with BED &gt;70Gy combined with Gemcitabine + albumin-bound paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>SBRT: in 5-6 fractions with CyberKnife</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>1000 mg of Gemcitabine + albumin-bound paclitaxel per square meter of body surface area on days 1, 8 for 2 weeks, followed by 1 weeks of rest as one course</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18≤Age≤75 years&#xD;
&#xD;
          -  Cytologically or histologically verified pancreatic adenocarcinoma or clinically&#xD;
             diagnosed as pancreatic cancer by multidisciplinary consultation&#xD;
&#xD;
          -  locally advanced pancreatic cancer (LAPC)&#xD;
&#xD;
          -  SBRT was not preceded by any targeted antitumor therapy&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
          -  Written informed consent according to ICH/GCP regulations before registration and&#xD;
             prior to any trial specific procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have previously received related treatment because of pancreatic&#xD;
             adenocarcinoma, such as radiotherapy, chemotherapy or focal treatment&#xD;
&#xD;
          -  Patients with severe liver or kidney dysfunction&#xD;
&#xD;
          -  Patients with obstructive jaundice&#xD;
&#xD;
          -  Patients with mass ascites&#xD;
&#xD;
          -  Patients participated in other clinical trials for less than three months&#xD;
&#xD;
          -  Patients with other malignancies, or acute or other severe infections, with ulcerative&#xD;
             colitis, inflammatory bowel disease, ect&#xD;
&#xD;
          -  Unsuitable to participate in this clinical trial judged by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Huojun Zhang, M.D.</last_name>
    <phone>021-31162222</phone>
    <email>chyyzhj@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yusheng Ye, M.D.</last_name>
    <phone>021-31162222</phone>
    <email>yusheng97y@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Changhai hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huojun Zhang, M.D.</last_name>
      <phone>+8613311732399</phone>
      <email>chyyzhj@163.com</email>
    </contact>
    <investigator>
      <last_name>Huojun Zhang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huojun Zhang, M.D.</last_name>
      <phone>021-31162222</phone>
      <email>chyyzhj@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2020</study_first_posted>
  <last_update_submitted>October 27, 2020</last_update_submitted>
  <last_update_submitted_qc>October 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Zhang Huo Jun</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>SBRT</keyword>
  <keyword>Locally Advanced Pancreatic Cancer</keyword>
  <keyword>Biological Effective Dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

